Remdesivir to charge hundreds per vial, more if patient’s privately insured

Gilead Sciences Inc. GILD -1.22% detailed its pricing plans for Covid-19 drug remdesivir, saying it will charge U.S. hospitals $ 3,120 for a typical patient with commercial insurance. The drugmaker on …
Independent Sentinel < continue reading